In an interim analysis of a phase 3 trial in adults with IgA nephropathy and persistent proteinuria, ravulizumab every 8 weeks lowered urinary protein-to-creatinine ratio at week 34 by 43.4% versus placebo (−46.6% vs −5.6%; P<0.001).
RCTn = 485
Barratt et al. Ravulizumab in IgA Nephropathy - Interim Analysis of a Phase 3 Trial